Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
Pompe's disease (glycogen storage disease type II) is an autosomal recessive myopathy caused by lysosomal alpha-glucosidase deficiency. Enzyme replacement therapy (ERT) is currently under development for this disease. We evaluated the morphological changes in muscle tissue of four children with infantile Pompe's disease who received recombinant human alpha-glucosidase from rabbit milk for 72 weeks. The patients were 2.5-8 months of age at entry. Prior to treatment, all patients showed lysosomal glycogen storage in skeletal and smooth muscle cells, vascular endothelium, Schwann cells, and perineurium. The first response to treatment was noticed in vascular endothelium and in peripheral nerves after 12 weeks of treatment at an enzyme dose of 15-20 mg/kg. Increasing the dose to 40 mg/kg led, after 72 weeks of treatment, to a reduction of glycogen storage and substantial improvement of muscle architecture in the least affected patient. Not all patients responded equally well, possibly due to differences in degree of glycogen storage and concomitant muscle pathology at the start of treatment. We conclude that intravenous administration of recombinant human alpha-glucosidase from rabbit milk can improve muscle morphology in classic infantile Pompe's disease when treatment is started before irreversible damage has occurred.
Winkel
Léon P F
LP
Department of Pediatrics, Erasmus MC-Sophia, Rotterdam, The Netherlands.
Kamphoven
Joep H J
JH
van den Hout
Hannerieke J M P
HJ
Severijnen
Lies A
LA
van Doorn
Pieter A
PA
Reuser
Arnold J J
AJ
van der Ploeg
Ans T
AT
D000818:Animals; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure; D005260:Female; D006003:Glycogen / Q000378:metabolism; D006009:Glycogen Storage Disease Type II / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D007223:Infant; D008247:Lysosomes / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure; D008297:Male; D008854:Microscopy, Electron; D018485:Muscle Fibers, Skeletal / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure; D018482:Muscle, Skeletal / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology*; D032389:Myocytes, Smooth Muscle / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure; D010525:Peripheral Nerves / Q000378:metabolism / Q000473:pathology; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012583:Schwann Cells / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome; D000520:alpha-Glucosidases / Q000172:deficiency / Q000494:pharmacology* / Q000627:therapeutic use*
D011993:Recombinant Fusion Proteins; D006003:Glycogen; D000520:alpha-Glucosidases